Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Science staff profile

 

Professor Mike Eccles

PositionProfessor
DepartmentDepartment of Pathology (DSM)
QualificationsBSc(Hons)(Massey) PhD(Otago)
Research summaryGenetic, environmental and epigenetic (developmental) mechanisms in cancer
TeachingContributor to the Genetics and BBiomedSci programmes (particularly postgraduate student supervision)
Memberships
  • New Zealand Organisation for Rare Disorders Executive Committee member.
  • Director, New Zealand Institute for Rare Disease Research Limited.
  • Melanoma Network (MelNet; A melanoma network in NZ) Executive Committee member.
  • Health Research South Board member.
  • Steering Committee member, Genetics Otago, University of Otago.
  • Steering Committee member, Centre for Reproduction and Genomics, University of Otago.
  • Kidney in Health and Disease Research Network Executive Committee member, University of Otago.
  • Member of Maurice Wilkins Centre CoRE.
  • Member of the Centre for Translational Cancer Research, University of Otago.
  • Member National Melanoma Standards Working Group.
    • Principal Investigator (non-management) Maurice Wilkins Centre for Molecular Biodiscovery (newly funded term, 2015-2018)
    • Member, F1000Prime
    • New Zealand Organisation for Rare Disorders Executive Committee
    • Director, New Zealand Institute for Rare Disease Research Limited
    • MelNet (A melanoma network in NZ) Executive Committee
    • Centre for Translational Cancer Research
    • Pathology Department Executive Committee
    • Pathology Department Research Committee
    • HTRU Management Committee
    • Board member ANZNET Neuroendocrine Tumour Research Group
ClinicalClinical interest: Genetics and genomics in translational medicine

Research

Presently, I specialise in molecular cancer research, with expertise in cancer genetics, human molecular genetics, and developmental genetics. My research background involves gene and chromosome mapping, epigenetic studies of gene regulation, and impacts on cell behaviour of gene expression. I head the Developmental Genetics and Pathology Laboratory in the Pathology Department, Dunedin School of Medicine, and am currently very interested in genetic, environmental, and epigenetic mechanisms of cancer in relation to developmental biology and cancer / overgrowth diseases.

My research for some years has been focused on PAX genes in development and cancer / overgrowth diseases, and I have also have a continuing focus on epigenetics / genomic imprinting research in childhood cancer. More recently I have been turning my attention to melanoma. I am a founding member of both MelNet, a network of melanoma professionals in NZ, and of NZORD, the NZ Organisation for Rare Diseases.

Current research interests are to:

  1. Identify genomic and epigenomic features characterising metastatic versus primary melanomas
  2. Investigate transcriptomic and signalling pathways cooperating with PAX genes in promoting tumourigenesis

Additional details

The Chair in Cancer Pathology was funded and established in 2006 in the Pathology Department at the University of Otago in partnership with the NZ Institute for Cancer Research Trust ("the NZICR Trust"). The NZICR Trust is also presently supporting a research fellow (Dr Aniruddha Chatterjee) in the Chair in Cancer Pathology's laboratory. Professor Eccles is the inuagural Professor to hold the Chair in Cancer Pathology (2006-present).

Publications

Roy, R., Chatterjee, A., Das, D., Ray, A., Singh, R., Chattopadhyay, E., … Eccles, M., … Roy, B. (2019). Genome-wide miRNA methylome analysis in oral cancer: Possible biomarkers associated with patient survival. Epigenomics, 11(5), 473-487. doi: 10.2217/epi-2018-0078

Chatterjee, A., Ahn, A., Rodger, E. J., Stockwell, P. A., & Eccles, M. R. (2018). A guide for designing and analyzing RNA-Seq data. In N. Raghavachari & N. Garcia-Reyero (Eds.), Gene expression analysis: Methods in molecular biology (Vol. 1783). (pp. 35-80). New York, NY: Humana Press. doi: 10.1007/978-1-4939-7834-2_3

Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018). Epigenetic drivers of tumourigenesis and cancer metastasis. Seminars in Cancer Biology, 51, 149-159. doi: 10.1016/j.semcancer.2017.08.004

Bowden, S. A., Rodger, E. J., Bates, M., Chatterjee, A., Eccles, M. R., & Stayner, C. (2018). Genome-scale single nucleotide resolution analysis of DNA methylation in human autosomal dominant polycystic kidney disease. American Journal of Nephrology, 48(6), 415-424. doi: 10.1159/000494739

Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M., Motwani, J., … Eccles, M. R., & Hersey, P. (2018). Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. iScience. Advance online publication. doi: 10.1016/j.isci.2018.05.021

Chapter in Book - Research

Chatterjee, A., Ahn, A., Rodger, E. J., Stockwell, P. A., & Eccles, M. R. (2018). A guide for designing and analyzing RNA-Seq data. In N. Raghavachari & N. Garcia-Reyero (Eds.), Gene expression analysis: Methods in molecular biology (Vol. 1783). (pp. 35-80). New York, NY: Humana Press. doi: 10.1007/978-1-4939-7834-2_3

Chatterjee, A., Rodger, E. J., Morison, I. M., Eccles, M. R., & Stockwell, P. A. (2017). Tools and strategies for analysis of genome-wide and gene-specific DNA methylation patterns. In G. J. Seymour, M. P. Cullinan & N. C. K. Heng (Eds.), Oral biology: Molecular techniques and applications: Methods in molecular biology (Vol. 1537). (2nd ed.) (pp. 249-277). New York, NY: Springer. doi: 10.1007/978-1-4939-6685-1_15

Yoon, H.-S., & Eccles, M. R. (2011). Mild forms of Alport syndrome: Hereditary nephropathy in the absence of extra-renal features. In S. S. Prabhakar (Ed.), An update of glomerulopathies: Clinical and treatment aspects. (pp. 417-436). Rijeka, Croatia: InTech. Retrieved from http://www.intechopen.com

Eccles, M. R. (2008). PAX2 and the Renal-Coloboma Syndrome. In C. J. Epstein, R. P. Erickson & A. Wynshaw-Boris (Eds.), Inborn errors of development: The molecular basis of clinical disorders of morphogenesis. (2nd ed.) (pp. 796-802). Oxford University Press.

Eccles, M. R. (2004). PAX2 and the renal-coloboma syndrome. In C. J. Epstein, R. P. Erickson & A. Wynshaw-Boris (Eds.), Inborn errors of development: The molecular basis of clinical disorders of morphogenesis. (pp. 633-642). Oxford University Press.

Eccles, M. R., Bockett, N., & Stayner, C.-A. K. (2003). PAX2 and Renal-Coloboma Syndrome. In P. D. Vize, A. S. Woolf & J. B. L. Bard (Eds.), The kidney. (pp. 411-432). San Diego, USA: Elsevier Science.

^ Top of page

Journal - Research Article

Roy, R., Chatterjee, A., Das, D., Ray, A., Singh, R., Chattopadhyay, E., … Eccles, M., … Roy, B. (2019). Genome-wide miRNA methylome analysis in oral cancer: Possible biomarkers associated with patient survival. Epigenomics, 11(5), 473-487. doi: 10.2217/epi-2018-0078

Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018). Epigenetic drivers of tumourigenesis and cancer metastasis. Seminars in Cancer Biology, 51, 149-159. doi: 10.1016/j.semcancer.2017.08.004

Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M., Motwani, J., … Eccles, M. R., & Hersey, P. (2018). Marked global DNA hypomethylation is associated with constitutive PD-L1 expression in melanoma. iScience. Advance online publication. doi: 10.1016/j.isci.2018.05.021

Bowden, S. A., Rodger, E. J., Bates, M., Chatterjee, A., Eccles, M. R., & Stayner, C. (2018). Genome-scale single nucleotide resolution analysis of DNA methylation in human autosomal dominant polycystic kidney disease. American Journal of Nephrology, 48(6), 415-424. doi: 10.1159/000494739

Stayner, C., Brooke, D. G., Bates, M., & Eccles, M. R. (2018). Targeted therapies for autosomal dominant polycystic kidney disease. Current Medicinal Chemistry. Advance online publication. doi: 10.2174/0929867325666180508095654

Kaur, G., Li, C. G., Chantry, A., Stayner, C., Horsfield, J., & Eccles, M. R. (2018). SMAD proteins directly suppress PAX2 transcription downstream of transforming growth factor-beta 1 (TGF-β1) signalling in renal cell carcinoma. Oncotarget, 9(42), 26852-26867. doi: 10.18632/oncotarget.25516

Chatterjee, A., Macaulay, E. C., Ahn, A., Ludgate, J. L., Stockwell, P. A., Weeks, R. J., Parry, M. F., Foster, T. J., … Eccles, M. R., & Morison, I. M. (2017). Comparative assessment of DNA methylation patterns between reduced representation bisulfite sequencing and Sequenom EpiTyper methylation analysis. Epigenomics, 9(6), 823-832. doi: 10.2217/epi-2016-0176

Chatterjee, A., Stockwell, P. A., Ahn, A., Rodger, E. J., Leichter, A. L., & Eccles, M. R. (2017). Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis. Oncotarget, 8(4), 6085-6101. doi: 10.18632/oncotarget.14042

Ludgate, J. L., Wright, J., Stockwell, P. A., Morison, I. M., Eccles, M. R., & Chatterjee, A. (2017). A streamlined method for analysing genome-wide DNA methylation patterns from low amounts of FFPE DNA. BMC Medical Genomics, 10, 54. doi: 10.1186/s12920-017-0290-1

Macaulay, E. C., Chatterjee, A., Cheng, X., Baguley, B. C., Eccles, M. R., & Morison, I. M. (2017). The genes of life and death: A potential role for placental-specific genes in cancer: Active retrotransposons in the placenta encode unique functional genes that may also be used by cancer cells to promote malignancy. BioEssays, 39(11), 1700091. doi: 10.1002/bies.201700091

Leichter, A. L., Sullivan, M. J., Eccles, M. R., & Chatterjee, A. (2017). MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. Molecular Cancer, 16(1), 15. doi: 10.1186/s12943-017-0584-0

Stayner, C., Poole, C. A., McGlashan, S. R., Pilanthananond, M., Brauning, R., Markie, D., … Slobbe, L., … Parker, K., Wiles, A., … Leichter, A., Leask, M., … Jennings, M., Horsfield, J. A., Walker, R. J., & Eccles, M. R. (2017). An ovine hepatorenal fibrocystic model of a Meckel-like syndrome associated with dysmorphic primary cilia and TMEM67 mutations. Scientific Reports, 7, 1601. doi: 10.1038/s41598-017-01519-4

Jones, A. M., Ferguson, P., Gardner, J., Rooker, S., Sutton, T., Ahn, A., Chatterjee, A., … Sarwar, M., Emanuel, P., Kenwright, D., … Eccles, M. R. (2016). NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand. Oncotarget, 7(27), 41017-41030. doi: 10.18632/oncotarget.9351

Moktefi, A., Zhang, S.-Y., Vachin, P., Ory, V., Henique, C., Audard, V., … Eccles, M., … Pawlak, A. (2016). Repression of CMIP transcription by WT1 is relevant to podocyte health. Kidney International, 90(6), 1298-1311. doi: 10.1016/j.kint.2016.07.016

Chatterjee, A., Stockwell, P. A., Rodger, E. J., Parry, M. F., & Eccles, M. R. (2016). scan_tcga tools for integrated epigenomic and transcriptomic analysis of tumor subgroups. Epigenomics, 8(10), 1315-1330. doi: 10.2217/epi-2016-0063

Mainini, F., Larsen, D. S., Webster, G. A., Young, S. L., & Eccles, M. R. (2015). Bridging small molecules to modified bacterial microparticles using a disulphide linkage: MIS416 as a cargo delivery system. PLoS ONE, 10(12), e0145403. doi: 10.1371/journal.pone.0145403

Kunnen, B., Macdonald, C., Doronin, A., Jacques, S., Eccles, M., & Meglinski, I. (2015). Application of circularly polarized light for non-invasive diagnosis of cancerous tissues and turbid tissue-like scattering media. Journal of Biophotonics, 8(4), 317-323. doi: 10.1002/jbio.201400104

Pinnapureddy, A. R., Stayner, C., McEwan, J., Baddeley, O., Forman, J., & Eccles, M. R. (2015). Large animal models of rare genetic disorders: Sheep as phenotypically relevant models of human genetic disease. Orphanet Journal of Rare Diseases, 10, 107. doi: 10.1186/s13023-015-0327-5

Chatterjee, A., Leichter, A. L., Fan, V., Tsai, P., Purcell, R. V., Sullivan, M. J., & Eccles, M. R. (2015). A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients. Scientific Reports, 5, 10438. doi: 10.1038/srep10438

Leichter, A. L., Purcell, R. V., Sullivan, M. J., Eccles, M. R., & Chatterjee, A. (2015). Multi-platform microRNA profiling of hepatoblastoma patients using formalin fixed paraffin embedded archival samples. GigaScience, 4, 54. doi: 10.1186/s13742-015-0099-9

Eccles, M. R., & Stayner, C. A. (2014). Polycystic kidney disease: Where gene dosage counts. F1000 Prime Reports, 6, 24. doi: 10.12703/p6-24

Hung, N., Chen, Y.-J., Taha, A., Olivecrona, M., Boet, R., Wiles, A., … Shaw, A., Eiholzer, R., Baguley, B. C., Eccles, M. R., Braithwaite, A. W., MacFarlane, M., Royds, J. A., & Slatter, T. (2014). Increased paired box transcription factor 8 has a survival function in Glioma. BMC Cancer, 14, 159. doi: 10.1186/1471-2407-14-159

Stevens, A. J., Stuffrein-Roberts, S., Cree, S. L., Gibb, A., Miller, A. L., Doudney, K., Aitchison, A., Eccles, M. R., Joyce, P. R., … Kennedy, M. A. (2014). G-quadruplex structures and CpG methylation cause drop-out of the maternal allele in polymerase chain reaction amplification of the imprinted MEST gene promoter. PLoS ONE, 9(12), e113955. doi: 10.1371/journal.pone.0113955

Eccles, M. R., He, S., Ahn, A., Slobbe, L. J., Jeffs, A. R., Yoon, H.-S., & Baguley, B. C. (2013). MITF and PAX3 play distinct roles in melanoma cell migration: Outline of a “genetic switch” theory involving MITF and PAX3 in proliferative and invasive phenotypes of melanoma. Frontiers in Oncology, 3, 229. doi: 10.3389/fonc.2013.00229

Wu, M. K., Sabbaghian, N., Xu, B., Addidou-Kalucki, S., Bernard, C., Zou, D., Reeve, A. E., Eccles, M. R., … Foulkes, W. D. (2013). Biallelic DICER1 mutations occur in Wilms tumours. Journal of Pathology, 230(2), 154-164. doi: 10.1002/path.4196

Bower, M., Salomon, R., Allanson, J., Antignac, C., Benedicenti, F., Benetti, E., … Dixon, J., … Eccles, M., … Heidet, L. (2012). Update of PAX2 mutations in renal coloboma syndrome and establishment of locus-specific database. Human Mutation, 33(3), 457-466. doi: 10.1002/humu.22020

Ineson, J., Stayner, C., Hazlett, J., Slobbe, L., Robson, E., Legge, M., & Eccles, M. R. (2012). Somatic reactivation of expression of the silent maternal Mest allele and acquisition of normal reproductive behaviour in a colony of Peg1/Mest mutant mice. Journal of Reproduction & Development, 58(4), 490-500.

Burger, M. C., Brucker, D. P., Baumgarten, P., Ronellenfitsch, M. W., Wanka, C., Hasselblatt, M., Eccles, M. R., … Steinbach, J. P. (2012). PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. International Journal of Oncology, 41(1), 235-241. doi: 10.3892/ijo.2012.1446

Stayner, C., Shields, J., Slobbe, L., Shillingford, J. M., Weimbs, T., & Eccles, M. R. (2012). Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: An investigation of the feasibility of renal cyst prevention in the foetus. Nephrology, 17(8), 739-747. doi: 10.1111/j.1440-1797.2012.01639.x

McEwan, M. V., Eccles, M. R., & Horsfield, J. A. (2012). Cohesin is required for activation of MYC by estradiol. PLoS ONE, 7(11), e49160. doi: 10.1371/journal.pone.0049160

Li, C. G., & Eccles, M. R. (2012). PAX genes in cancer: Friends or foes? Frontiers in Genetics, 3, 6. doi: 10.3389/fgene.2012.00006

He, S., Li, C. G., Slobbe, L., Glover, A., Marshall, E., Baguley, B. C., & Eccles, M. R. (2011). PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma Research, 21(1), 24-34. doi: 10.1097/CMR.0b013e328341c7e0

Li, C. G., Nyman, J. E., Braithwaite, A. W., & Eccles, M. R. (2011). PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene, 30, 4824-4834. doi: 10.1038/onc.2011.190

Otto, E. A., Ramaswami, G., Janssen, S., Chaki, M., Allen, S. J., Zhou, W., … and the GPN Study Group, including Eccles, M. (2011). Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. Journal of Medical Genetics, 48, 105-116. doi: 10.1136/jmg.2010.082552

He, S., Yoon, H.-S., Suh, B.-J., & Eccles, M. R. (2010). PAX3 is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans [Letter]. Journal of Investigative Dermatology, 130, 1465-1468. doi: 10.1038/jid.2009.434

Mönnich, M., Banks, S., Eccles, M., Dickinson, E., & Horsfield, J. (2009). Expression of cohesin and condensin genes during zebrafish development supports a non-proliferative role for cohesin. Gene Expression Patterns, 9(8), 586-594. doi: 10.1016/j.gep.2009.08.004

Jeffs, A. R., Glover, A. C., Slobbe, L. J., Wang, L., He, S., Hazlett, J. A., Awasthi, A., Woolley, A. G., … Print, C. G., … Eccles, M. R. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PLoS ONE, 4(12), e8461. doi: 10.1371/journal.pone.0008461

Hueber, P.-A., Fukuzawa, R., Elkares, R., Chu, L., Blumentkrantz, M., He, S.-J., Anaka, M. R., Reeve, A. E., Eccles, M. R., … Goodyer, P. R. (2009). PAX3 is expressed in the stromal compartment of the developing kidney and in Wilms tumors with myogenic phenotype. Pediatric & Developmental Pathology, 12(5), 347-354. doi: 10.2350/08-05-0466.1

Chen, Y.-J., Campbell, H. G., Wiles, A. K., Eccles, M. R., Reddel, R. R., Braithwaite, A. W., & Royds, J. A. (2008). PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Research, 68(14), 5724-5732. doi: 10.1158/0008-5472.CAN-08-0058

Hueber, P.-A., Iglesias, D., Chu, L. L., Eccles, M., & Goodyer, P. (2008). In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Letters, 265, 148-155. doi: 10.1016/j.canlet.2008.02.016

Frost, V., Grocott, T., Eccles, M. R., & Chantry, A. (2008). Self-regulated Pax gene expression and modulation by the TGFβ superfamily. Critical Reviews in Biochemistry & Molecular Biology, 43(6), 371-391. doi: 10.1080/10409230802486208

Wilson, J. C., Yoon, H.-S., Walker, R. J., & Eccles, M. R. (2007). A novel Cys1638Tyr NC1 domain substitution in α5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities. Nephrology Dialysis Transplantation, 22(5), 1338-1346. doi: 10.1093/ndt/gfl793

Lu, W., van Eerde, A. M., Fan, X., Quintero-Rivera, F., Kulkarni, S., Ferguson, H., … Eccles, M. R., … Maas, R. L. (2007). Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. American Journal of Human Genetics, 80(4), 616-632. doi: 10.1086/512735

Schimmenti, L. A., & Eccles, M. R. (2007). Renal coloboma syndrome [Papillorenal syndrome]. GeneReviews. Seattle, USA: GeneTests, University of Washington. Retrieved from http://www.geneclinics.org/profiles/all.html#R

Torban, E., Dziarmaga, A., Iglesias, D., Chu, L. L., Vassilieva, T., Little, M., Eccles, M., … Goodyer, P. (2006). PAX2 activates WNT4 expression during mammalian kidney development. Journal of Biological Chemistry, 281(18), 12705-12712.

Hueber, P.-A., Waters, P., Clarke, P., Eccles, M., & Goodyer, P. (2006). PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney International, 69, 1139-1145.

Stayner, C., Iglesias, D. M., Goodyer, P. R., Ellis, L., Germino, G., Zhou, J., & Eccles, M. R. (2006). Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Human Molecular Genetics, 15(24), 3520-3528.

Utsch, B., Sayer, J. A., Attanasio, M., Pereira, R. R., Eccles, M., Hennies, H.-C., … Hildebrandt, F. (2006). Identification of the first AHI1 gene mutations in nephronophthisis-associated Joubert syndrome. Pediatric Nephrology, 21, 32-35.

Dziarmaga, A., Eccles, M., & Goodyer, P. (2006). Suppression of ureteric bud apoptosis rescues nephron endowment and adult renal function in Pax2 mutant mice. Journal of the American Society of Nephrology, 17, 1568-1575.

Robson, E. J. D., He, S.-J., & Eccles, M. R. (2006). A PANorama of PAX genes in cancer and development. Nature Reviews Cancer, 6, 52-62.

Dziarmaga, A., Hueber, P.-A., Iglesias, D., Hache, N., Jeffs, A., Gendron, N., … Eccles, M., & Goodyer, P. (2006). Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. American Journal of Physiology: Renal Physiology, 291, F913-F920. doi: 10.1152/ajprenal.00004.2006

Johnstone, A. C., Davidson, B. I., Roe, A. R., Eccles, M. R., & Jolly, R. D. (2005). Congenital polycystic kidney disease in lambs. New Zealand Veterinary Journal, 53(5), 307-314.

He, S.-J., Stevens, G., Braithwaite, A. W., & Eccles, M. R. (2005). Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Molecular Cancer Therapeutics, 4(6), 996-1003.

Filipovska, A., Eccles, M. R., Smith, R. A. J., & Murphy, M. P. (2004). Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEBS Letters, 556, 180-186.

Clark, P., Dziarmaga, A., Eccles, M., & Goodyer, P. (2004). Rescue of defective branching nephrogenesis in renal-coloboma syndrome by the caspase inhibitor, Z-VAD-fmk. Journal of the American Society of Nephrology, 15, 299-305.

Muratovska, A., & Eccles, M. R. (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Letters, 558, 63-68.

Fukuzawa, R., Eccles, M. R., Ikeda, M., & Hata, J.-I. (2003). Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations. Pediatric Nephrology, 18(1), 9-13.

Dziarmaga, A., Clark, P., Stayner, C.-A. K., Julien, J. P., Torban, E., Goodyer, P., & Eccles, M. R. (2003). Ureteric bud apoptosis and renal hypoplasia in transgenic PAX2-Bax fetal mice mimics the renal-coloboma syndrome. Journal of the American Society of Nephrology, 14(11), 2767-2774.

Muratovska, A., Zhou, C., He, S., Goodyer, P., & Eccles, M. R. (2003). Paired-box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene, 22(39), 7989-7997.

Edwards, S. J., Hananeia, L., Eccles, M. R., Zhang, Y.-F., & Braithwaite, A. (2003). The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene, 22(29), 4517-4523.

Discenza, M. T., He, S., Lee, T. H., Chu, L. L., Bolon, B., Goodyer, P., Eccles, M., & Pelletier, J. (2003). WT1 is a modifier of the Pax2 mutant phenotype: Cooperation and interaction between WT1 and Pax2. Oncogene, 22(50), 8145-8155. doi: 10.1038/sj.onc.1206997

Gough, S. M., McDonald, M., Chen, X.-N., Korenberg, J. R., Neri, A., Kahn, T., Eccles, M. R., & Morris, C. M. (2003). Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1. BMC Genomics, 4(1), 9.

Eccles, M. R., He, S., Legge, M., Kumar, R., Fox, J., Zhou, C., French, M., & Tsai, R. (2002). PAX genes in development and disease: The role of PAX2 in urogenital tract development. International Journal of Developmental Biology, 46, 535-544.

Gus, P. I., de Souza, C. F. M., Porteous, S. H., & Eccles, M. R. (2001). Renal-coloboma syndrome in a Brazilian family. Archives of Ophthalmology, 119(2), 1563-1565.

Walker, R. J., Dixon, S., Ruger, B. M., Davis, P. F., Hildebrant, F., Kremer, M., Eccles, M. R., McNoe, L. A., … Reid, J. J. (2001). Familial fibronectin glomerulopathy: Analysis of chromosome 1q32 and uteroglobulin gene loci in a large New Zealand family. Nephrology, 6, 191-197.

Chen, F., Colin, G. B., Liu, K. C., Beier, D. R., Eccles, M. R., Nishina, P. M., … Epstein, J. A. (2001). Characterization of the Murine Lbx2 promoter, identification of the human homologue, and evaluation as a candidate for Alstrom syndrome. Genomics, 74(2), 219-227.

Torban, E., Eccles, M. R., Favor, J., & Goodyer, P. (2000). PAX2 suppresses apoptosis in renal collecting duct cells. American Journal of Pathology, 157(3), 833-842.

Amiel, J., Audollent, S., Joly, D., Dureau, P., Salomon, R., Tellier, A. L., … Eccles, M. R., … Attie-Bitach, T. (2000). PAX2 mutations in renal-coloboma syndrome: Mutational hotspot and germline mosaicism. European Journal of Human Genetics, 8(11), 820-826.

Eccles, M. R., & Jacobs, G. H. (2000). The genetics of primary vesico - ureteric reflux. Annals Academy Medicine Singapore, 29, 337-345.

Morison, I. M., Eccles, M. R., & Reeve, A. E. (2000). Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis. Blood, 96(9), 3023-3028.

Ades, L., Davies, R., Haan, E. A., Holman, K. J., Watson, K. C., Sreetharan, D., … Eccles, M. R., McNoe, L. A., & Harbord, M. (2000). Aortic dissection patent ductus arteriosus, iris hypoplasia and brachytelephalangy in a male adolescent. Clinical Dysmorphology, 8, 269-276.

Porteous, S., Torban, E., Cho, N.-P., Cunliffe, H. E., Chua, L. J., McNoe, L. A., Ward, T. A., … Yun, K., … Eccles, M. R. (2000). Primary renal hypoplasia in humans and mice with PAX2 mutations: Evidence of increased apoptosis in fetal kidneys of PAX2(1NEU)+/-mutant mice. Human Molecular Genetics, 9(1), 1-11.

Eccles, M. R., & Schimmenti, L. A. (1999). Renal-coloboma syndrome: a multi-system developmental disorder caused by PAX2 mutations. Clinical Genetics, 56, 1-9.

Cunliffe, H. E., McNoe, L. A., Ward, T. A., Devriendt, K., Brunner, H. G., & Eccles, M. R. (1998). The prevalence of PAX2 mutations in patients with isolated colobomas or colobomas associated with urogenital anomalies. Journal of Medical Genetics, 35(10), 806-812.

Stayner, C. K., Cunliffe, H. E., Ward, T. A., & Eccles, M. R. (1998). Cloning and characterization of the human PAX2 promoter. Journal of Biological Chemistry, 273(39), 25472-25479.

Devriendt, K., Matthijs, G., Van Damme, B., Van Caesbroeck, D., Eccles, M. R., Vanrenterghem, Y., … Leys, A. (1998). Missense mutation and hexanucleotide duplication in the PAX2 gene in two unrelated families with renal-coloboma syndrome (MIM 120330). Human Genetics, 103, 149-153.

Choi, K.-L., McNoe, L. A., French, M. C., Guilford, P. J., & Eccles, M. R. (1998). Absence of PAX2 gene mutations in patients with primary familial vesicoureteric reflux. Journal of Medical Genetics, 35(4), 338-339. doi: 10.1136/jmg.35.4.338

Schimmenti, L. A., Cunliffe, H. E., McNoe, L. A., Ward, T. A., French, M., Shim, H. H., … Eccles, M. R. (1997). Further delineation of renal-coloboma syndrome in patients with extreme variability of phenotype and identical PAX2 mutations. American Journal of Human Genetics, 60(4), 869-878.

McConnell, M. J., Cunliffe, H. E., Chua, L. J., Ward, T. A., & Eccles, M. R. (1997). Differential regulation of the human Wilms-tumour suppressor gene (WT1) promoter by two isoforms of PAX2. Oncogene, 14(22), 2689-2700. doi: 10.1038/sj.onc.1201114

Erickson, R. P., Stone, J. F., McNoe, L. A., & Eccles, M. R. (1997). Molecular and clinical studies of three cases of female pseudohermaphroditism with caudal dysplasia suggest multiple etiologies. Clinical Genetics, 51(5), 331-337.

Narahara, K., Baker, E., Ito, S., Yokoyama, Y., Yu, S., Hewitt, D., … Eccles, M. R., & Richards, R. I. (1997). Localisation of a 10q breakpoint within the PAX2 gene in a patient with a de novo t(10;13) translocation and optic nerve coloboma renal disease. Journal of Medical Genetics, 34(3), 213-216.

Eccles, M. R., Bailey, R. R., Sullivan, M. J., & Abbott, G. D. (1996). Unravelling the genetics of vesicoureteric reflux: a common familial disorder. Human Molecular Genetics, 5, 1425-1429.

Sanyanusin, P., Norrish, J. H., Ward, T. A., Nebel, A., McNoe, L. A., & Eccles, M. R. (1996). Genomic structure of the human PAX2 gene. Genomics, 35(1), 258-261.

^ Top of page

Journal - Research Other

Mainini, F., Larsen, D. S., Webster, G. A., Young, S. L., & Eccles, M. R. (2018). MIS416 as a siRNA delivery system with the ability to target antigen-presenting cells [Brief communication]. Nucleic Acid Therapeutics. Advance online publication. doi: 10.1089/nat.2017.0695

Eccles, M. R., Chatterjee, A., & Rodger, E. J. (2017). Identifying drivers of metastasis; towards a systematic approach. Translational Cancer Research, 6(Suppl. 7), S1273-S1276. doi: 10.21037/tcr.2017.09.52

Ahn, A., Chatterjee, A., & Eccles, M. R. (2017). The slow cycling phenotype: A growing problem for treatment resistance in melanoma. Molecular Cancer Therapeutics, 16(6), 1002-1009. doi: 10.1158/1535-7163.mct-16-0535

Eccles, M. R. (2013). Melanoma Genetics/Genomics. Frontiers in Oncology, 3, 309. doi: 10.3389/fonc.2013.00309

Ahn, A., & Eccles, M. R. (2013). Targeted therapy: From advanced melanoma to the adjuvant setting. Frontiers in Oncology, 3. doi: 10.3389/fonc.2013.00205

Duncan, G., Stevens, G., Boberg, C., Harman, R., Eccles, M., Marshall, B., … Rademaker, M. (2011). Melanoma Summit highlights best practice and priorities for action [Letter]. New Zealand Medical Journal, 124(1334). Retrieved from http://journal.nzma.org.nz/journal/124-1334/4670/content.pdf

Eccles, M. (2011). Is cancer the next of kin to the developing foetus? Australasian Science, 32(10), 26-27.

Bower, M., Eccles, M., Heidet, L., & Schimmenti, L. A. (2011). Clinical utility gene card for: Renal coloboma (Papillorenal) syndrome. European Journal of Human Genetics, 19(9). doi: 10.1038/ejhg.2011.16

More publications...